BET inhibitor pelabresib (CPI-0610) combined with ruxolitinib in patients with myelofibrosis - JAK inhibitor-naive or with suboptimal response to ruxolitinib - Preliminary data from the MANIFEST study Meeting Abstract
| Authors: | Mascarenhas, J.; Kremyanskaya, M.; Patriarca, A.; Harrison, C.; Bose, P.; Rampal, R. K.; Palandri, F.; Devos, T.; Passamonti, F.; Hobbs, G.; Talpaz, M.; Vannucchi, A.; Kiladjian, J. J.; Verstovsek, S.; Hoffman, R.; Salama, M. E.; Chen, D.; Taverna, P.; Chang, A.; Colak, G.; Klein, S.; Gupta, V. |
| Abstract Title: | BET inhibitor pelabresib (CPI-0610) combined with ruxolitinib in patients with myelofibrosis - JAK inhibitor-naive or with suboptimal response to ruxolitinib - Preliminary data from the MANIFEST study |
| Meeting Title: | 10th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | myelofibrosis; epigenetics; bet; ruxolitinib; mpn; pelabresib; trial-in-progress |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 22 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2022 Sep 28-Oct 1 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-10-01 |
| Start Page: | S335 |
| End Page: | S336 |
| Language: | English |
| ACCESSION: | WOS:000897948100335 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(22)01456-2 |
| Notes: | Meeting Abstract: MPN-375 -- Source: Wos |
